Top

Journal of Gastrointestinal Cancer

Published in:

01-09-2020 | Hepatocellular Carcinoma | Original Research

May Neutrophil Gelatinase-Associated Lipocalin (NGAL) Level Predict Mortality in Patients with Hepatocellular Carcinoma (HCC)?

Authors: Ramazan Dertli, Murat Biyik, Ramazan Yolacan, Ahmet Karakarcayildiz, Muharrem Keskin, Yusuf Kayar, Mehmet Asil

Published in: Journal of Gastrointestinal Cancer | Issue 3/2020

Abstract

Purpose

Hepatocellular carcinoma (HCC) ranks fifth among the common cancers worldwide. Hepatocarcinogenesis is a multiple-phases process, which involves changes in cellular genomes including high cell proliferation.In this study, we aimed to evaluate the relationship of NGAL level at the time of diagnosis with mortality in patients diagnosed with HCC.

Material and Methods

A total of 35 patients who developed HCC on the ground of HBV(+) and 30 healthy subjects were included in the study. Barcelona Clinic Liver Cancer (BCLC), Okuda staging system, and Milan criteria were used for staging of the patients with HCC.

Results

The mean age of all patients was 59.54 ± 11.57 years. Seventeen (48.6%) HCC patients died during 1-year follow-up. Survival of the patients who met the Milan criteria was longer (log-rank (Mantel-Cox) test, χ2 = 5.353, p = 0.021). Kaplan-Meier curve was drawn for NGAL cut-off value, mortality was found to be higher in patients with a NGAL level higher than 217.50 (log-rank (Mantel-Cox) test, χ2 = 15.540, p < 0.001).

Conclusion

In this study, we found that high levels of NGAL at the time of diagnosis were associated with poor prognosis in HCC patients.

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30.PubMed

Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol. 2009;27(9):1485–91.PubMedPubMedCentral

Forner A, Llovet JM, Bruix J. Hepatocellularcarcinoma. Lancet. 2012;379(9822):1245.

Huang YH, Wu JC, Chen CH, Chang TT, Lee PC, Chau GY, et al. Comparison of recurrence after hepatic resection in patients with hepatitis B vs. hepatitis C-related small hepatocellular carcinoma in hepatitis B virus endemic area. Liver Int. 2005;25(2):236–41.PubMed

Mehmet A, Dertli R. Serum soluble TWEAK concentration is decreased in patients with hepatocellular cancer and low blood levels of sTWEAK are associated with poor survival. Int J Hematol Oncol. 27(2):118–26.

Cabiati M, Gaggini M, Cesare MM, Caselli C, De Simone P, Filipponi F, et al. Osteopontin in hepatocellular carcinoma: a possible biomarker for diagnosis and follow-up. Cytokine. 2017;99:59–65.PubMed

Rodvold JJ, Mahadevan NR, Zanetti M. Lipocalin 2 in cancer: when good immunity goes bad. Cancer Lett. 2012;316(2):132–8.PubMed

Li C, Chan YR. Lipocalin 2 regulation and its complex role in inflammation and cancer. Cytokine. 2011;56(2):435–41.PubMed

Jin D, Zhang Y, Chen X. Lipocalin 2 deficiency inhibits cell proliferation, autophagy, and mitochondrial biogenesis in mouse embryonic cells. Mol Cell Biochem. 2011;351(1-2):165–72.PubMed

10.

Leng X, Wu Y, Arlinghaus RB. Relationships of lipocalin 2 with breast tumorigenesis and metastasis. J Cell Physiol. 2011;226(2):309–14.PubMed

11.

Lin H-H, Liao C-J, Lee Y-C, Hu K-H, Meng H-W, Chu S-T. Lipocalin-2-induced cytokine production enhances endometrial carcinoma cell survival and migration. Int J Biol Sci. 2011;7(1):74–86.PubMedPubMedCentral

12.

Lim R, Ahmed N, Borregaard N, Riley C, Wafai R, Thompson EW, et al. Neutrophil gelatinase-associated lipocalin (NGAL) an early-screening biomarker for ovarian cancer: NGAL is associated with epidermal growth factor-induced epithelio-mesenchymal transition. Int J Cancer. 2007;120(11):2426–34.PubMed

13.

Furutani M, Arii S, Mizumoto M, Kato M, Imamura M. Identification of a neutrophil gelatinase-associated lipocalin mRNA in human pancreatic cancers using a modified signal sequence trap method. Cancer Lett. 1998;122(1):209–14.PubMed

14.

Kubben FJ, Sier CF, Hawinkels LJ, Tschesche H, van Duijn W, Zuidwijk K, et al. Clinical evidence for a protective role of lipocalin-2 against MMP-9 autodegradation and the impact for gastric cancer. Eur J Cancer. 2007;43(12):1869–76.PubMed

15.

Barresi V, Vitarelli E, Bonetti LR, Tuccari G, Barresi G. Diagnostic value of neutrophil gelatinase-associated lipocalin (NGAL) immunoexpression in follicular-patterned lesions of the thyroid gland. Virchows Archiv. 2012;460(3):319–25.PubMed

16.

Ozemir IA, Aslan S, Eren T, Bayraktar B, Bilgic C, Isbilen B, et al. The diagnostic and prognostic significance of serum neutrophil gelatinase-associated lipocalin levels in patients with colorectal cancer. Chirurgia (Bucharest, Romania: 1990). 2016;111(5):414–21.

17.

Goetz DH, Holmes MA, Borregaard N, Bluhm ME, Raymond KN, Strong RK. The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition. Mol Cell. 2002;10(5):1033–43.PubMed

18.

Patil MA, Chua M-S, Kuang-Hung P, Lin R, Lih C-J, Cheung S-T, et al. An integrated data analysis approach to characterize genes highly expressed in hepatocellular carcinoma. Oncogene. 2005;24(23):3737.PubMed

19.

Lee E-K, Kim H-J, Lee K-J, Lee H-J, Lee J-S, Kim D-G, et al. Inhibition of the proliferation and invasion of hepatocellular carcinoma cells by lipocalin 2 through blockade of JNK and PI3K/Akt signaling. Int J Oncol. 2011;38(2):325–33.PubMed

20.

Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment study of 850 patients. Cancer. 1985;56(4):918–28.PubMed

21.

22.

Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334(11):693–700.PubMed

23.

Stejskal D, Karpíšek M, Humenanska V, Hanulova Z, Stejskal P, Kusnierova P, et al. Lipocalin-2: development, analytical characterization, and clinical testing of a new ELISA. Horm Metab Res. 2008;40(06):381–5.PubMed

24.

Giasson J, Hua Li G, Chen Y. Neutrophil gelatinase-associated lipocalin (NGAL) as a new biomarker for non-acute kidney injury (AKI) diseases. Inflamm Allergy Drug Targets (Formerly Current Drug Targets-Inflammation & Allergy). 2011;10(4):272–82.

25.

Mir SU, Jin L, Craven RJ. Neutrophil gelatinase-associated lipocalin (NGAL) expression is dependent on the tumor-associated sigma-2 receptor S2RPgrmc1. J Biol Chem. 2012;287(18):14494–501.PubMedPubMedCentral

26.

Yang J, Moses MA. Lipocalin 2: a multifaceted modulator of human cancer. Cell Cycle. 2009;8(15):2347–52.PubMedPubMedCentral

27.

Bouchet S, Bauvois B. Neutrophil gelatinase-associated lipocalin (NGAL), pro-matrix metalloproteinase-9 (pro-MMP-9) and their complex pro-MMP-9/NGAL in leukaemias. Cancers. 2014;6(2):796–812.PubMedPubMedCentral

28.

Zhang Y, Fan Y, Mei Z. NGAL and NGALR overexpression in human hepatocellular carcinoma toward a molecular prognostic classification. Cancer Epidemiol. 2012;36(5):e294–e9.PubMed

29.

Chuma M, Sakamoto M, Yamazaki K, Ohta T, Ohki M, Asaka M, et al. Expression profiling in multistage hepatocarcinogenesis: identification of HSP70 as a molecular marker of early hepatocellular carcinoma. Hepatology. 2003;37(1):198–207.PubMed

30.

Wang YP, Yu GR, Lee MJ, Lee SY, Chu IS, Leem SH, et al. Lipocalin-2 negatively modulates the epithelial-to-mesenchymal transition in hepatocellular carcinoma through the epidermal growth factor (TGF-beta1)/Lcn2/Twist1 pathway. Hepatology. 2013;58(4):1349–61.PubMed

31.

Jayaraman A, Roberts KA, Yoon J, Yarmush DM, Duan X, Lee K, et al. Identification of neutrophil gelatinase-associated lipocalin (NGAL) as a discriminatory marker of the hepatocyte-secreted protein response to IL-1β: a proteomic analysis. Biotechnol Bioeng. 2005;91(4):502–15.PubMed

32.

Cowland JB, Sørensen OE, Sehested M, Borregaard N. Neutrophil gelatinase-associated lipocalin is up-regulated in human epithelial cells by IL-1β, but not by TNF-α. J Immunol. 2003;171(12):6630–9.PubMed

33.

Moss SF, Blaser MJ. Mechanisms of disease: inflammation and the origins of cancer. Nat Clin Pract Oncol. 2005;2(2):90–7 quiz 1 p following 113.PubMed

34.

Nuntagowat C, Leelawat K, Tohtong R. NGAL knockdown by siRNA in human cholangiocarcinoma cells suppressed invasion by reducing NGAL/MMP-9 complex formation. Clin Exp Metastasis. 2010;27(5):295–305.PubMed

35.

Duvillard L, Ortega-Deballon P, Bourredjem A, Scherrer M-L, Mantion G, Delhorme J-B, et al. A case–control study of pre-operative levels of serum neutrophil gelatinase-associated lipocalin and other potential inflammatory markers in colorectal cancer. BMC Cancer. 2014;14(1):912.PubMedPubMedCentral

36.

Friedl A, Stoesz S, Buckley P, Gould M. Neutrophil gelatinase-associated lipocalin in normal and neoplastic human tissues. Cell type-specific pattern of expression. Histochem J. 1999;31(7):433–41.PubMed

37.

Di Carlo A. The enigmatic role of lipocalin 2 in human cancer. The multifunctional protein neutrophil gelatinase-associated lipocalin (NGAL) and its ambiguous role in human neoplasias. Prevent Res. 2012;2.

38.

Moniaux N, Chakraborty S, Yalniz M, Gonzalez J, Shostrom VK, Standop J, et al. Early diagnosis of pancreatic cancer: neutrophil gelatinase-associated lipocalin as a marker of pancreatic intraepithelial neoplasia. Br J Cancer. 2008;98(9):1540–7.PubMedPubMedCentral

39.

Tong Z, Wu X, Ovcharenko D, Zhu J, Chen C-S, Kehrer JP. Neutrophil gelatinase-associated lipocalin as a survival factor. Biochem J. 2005;391(2):441–8.PubMedPubMedCentral

Title: May Neutrophil Gelatinase-Associated Lipocalin (NGAL) Level Predict Mortality in Patients with Hepatocellular Carcinoma (HCC)?
Authors: Ramazan Dertli
Murat Biyik
Ramazan Yolacan
Ahmet Karakarcayildiz
Muharrem Keskin
Yusuf Kayar
Mehmet Asil
Publication date: 01-09-2020
Publisher: Springer US
Keywords: Hepatocellular Carcinoma
Hepatocellular Carcinoma
Published in: Journal of Gastrointestinal Cancer / Issue 3/2020
Print ISSN: 1941-6628
Electronic ISSN: 1941-6636
DOI: https://doi.org/10.1007/s12029-019-00323-9

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Material and Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2020

Racial Diversity in Hepatocellular Carcinoma in a Predominately African-American Population at an Urban Medical Center

Case series of Mesenchymal Hamartoma: a Rare Childhood Hepatic Neoplasm

Primary B Cell Lymphoma of the Pancreas

Correction to: Pattern and Significance of Tumour Budding in Colorectal Carcinomas Using ITBCC Guidelines: a Low Resource Setting Practice Observation

Physical Inactivity and Pancreatic Cancer Mortality

Pattern and Significance of Tumour Budding in Colorectal Carcinomas Using ITBCC Guidelines: a Low Resource Setting Practice Observation

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials